Cienfuegos, December 21 (RHC)-- The Cuban medication CIMAvax-EGF against advanced lung cancer has begun its final stage of clinical trials in the province of Cienfuegos.
Developed by the Havana-based Molecular Immunology Center, the Cuban vaccine is the first registered therapeutic treatment of its kind that generates antibodies against the patient's epidermal growth factor (EGF).
The antibodies generated by the drug inhibit and stop the proliferation of tumor cells, thus stabilizing the pathology, increasing survival and ostensibly improving the patients' quality of life.
Clinical trial lead researcher Yoana Herrera Leyva said that the aim is to assess the response of patients to high and normal doses of the vaccine, in order to customize the treatment.
Cuban Lung Cancer Vaccine Begins Final Stage of Clinical Trials
Matérias relacionadas
Comentários
Deixe um comentário
Todos os campos são requeridosMais vistas
- UJC confirmada como secretária-geral da FMJD
- Feira Internacional EXPOSUR 2025 foi encerrada com entrega do Grande Prêmio a Serviços Médicos Cubanos
- Cuba e Peru assinam memorando para cooperação esportiva
- Mais de 16.500 crianças palestinas assassinadas em Gaza
- Após 13 anos, Luka Modric se despede do Real Madri